Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Lytham Partners 2025 Investor Healthcare Summit taking place virtually on January 13, 2025. The fireside chat
Read More

Brain receptor study offers hope for preventing epilepsy after traumatic brain injury

A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can develop following traumatic brain injury. Published in Theranostics, the study highlights the important role played by a receptor in the brain called P2X7. It suggests how we could both reduce epilepsy risk and predict which patients are most at risk of developing PTE by targeting this receptor.
Read More

Healthy mouth, healthy baby: Experts emphasize oral health for expectant mothers

With the start of the new year, prioritizing women’s oral health should become a key resolution. Women’s oral health is about more than just a beautiful smile—it is a critical aspect of overall well-being that is often overlooked. From puberty to menopause and every stage in between, hormonal changes can significantly impact oral health, affecting everything from gum disease risk to overall systemic health.
Read More

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share. Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate th
Read More
Top